Metabolism and Nutrition Disorder, Obesity
Conditions
Brief summary
This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.
Interventions
DRUGliraglutide
Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Initiation of liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg (initiation is defined as no prescription of the same brand within the previous 12 months) * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability of the study
Exclusion criteria
-Patients or physicians who previously participated in interventional studies for liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg will not be eligible to participate in the study -For the full study, sites and patients included in the pilot will be excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with BMI not measured | Within 6 months before date of the first prescription | — |
| Number of patients with BMI above or equal to 30 kg/m^2 | Less than 6 months before date of first prescription | — |
| Number of patients with BMI above or equal to 27kg/m^2 and below 30 kg/m^2 and 1 or more comorbidity | Less than 6 months before date of first prescription | Dysglycaemia (Type 2 Diabetes Mellitus \[T2DM\] or prediabetes), hypertension, dyslipidaemia, obstructive sleep apnoea, and/or other weight-related comorbidities |
| Number of patients with above or equal to 27 kg/m^2 and below 30 kg/m^2 and no comorbidities | Less than 6 months before date of first prescription | Dysglycaemia (Type 2 Diabetes Mellitus \[T2DM\] or prediabetes), hypertension, dyslipidaemia, obstructive sleep apnoea, and/or other weight-related comorbidities. |
| Number of patients with BMI below 27 kg/m^2 | Less than 6 months before date of first prescription | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with liraglutide 1.2 or 1.8 mg prescriptions with dose information of 3.0 mg per day | From date of first prescription until 24 months | — |
| Number of patients with liraglutide 1.2 or 1.8 mg prescriptions and indication of weight management | From date of first prescription until 24 months | — |
| Number of patients with liraglutide 3.0 mg prescriptions who have reached a dose of 3.0 mg | By 12 weeks after first prescription date | While adhering to the dose escalation according to label |
| Number of patients with liraglutide 3.0 mg prescriptions and other GLP-1 receptor agonists prescribed during continued treatment with liraglutide 3.0 mg | From date of first prescription until 24 months | Number of patients |
| Number of patients with continued treatment with liraglutide 3.0 mg | From date of first prescription until 0-6 weeks; 7-12 weeks; 13-18 weeks; 19-24 months | Number of patients |
Countries
Germany, Italy
Outcome results
None listed